242 results on '"Plata-Salamán, Carlos"'
Search Results
2. Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study
3. Pharmacological Modulation of the Sigma 1 Receptor and the Treatment of Pain
4. Sigma-1 Receptor and Pain
5. The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol–Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers
6. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial
7. Efficacy and safety of co‐crystal of tramadol‐celecoxib ( CTC ) in acute moderate‐to‐severe pain after abdominal hysterectomy: A randomized, double‐blind, phase 3 trial ( STARDOM2 )
8. Celecoxib‐tramadol co‐crystal in patients with moderate‐to‐severe pain following bunionectomy with osteotomy: A phase 3, randomized, double‐blind, factorial, active‐ and placebo‐controlled trial
9. Pharmacokinetics of multiple doses of co‐crystal of tramadol–celecoxib: findings from a four‐way randomized open‐label phase I clinical trial
10. Sigma-1 Receptor and Pain
11. Single‐dose pharmacokinetics of co‐crystal of tramadol–celecoxib: Results of a four‐way randomized open‐label phase I clinical trial in healthy subjects
12. Brain Mechanisms in Wasting and Cachexia
13. Celecoxib‐tramadol co‐crystal in patients with moderate‐to‐severe pain following bunionectomy with osteotomy: A phase 3, randomized, double‐blind, factorial, active‐ and placebo‐controlled trial.
14. Co-crystals as a new approach to multimodal analgesia and the treatment of pain
15. Acute and Chronic Disease : Neurological Manifestations
16. Cytokine Action in the Nervous System at Pathophysiological Versus Pharmacological Concentrations
17. Umami Taste in the Forebrain of the Alert Macaque
18. Animal models of disease: preclinical to clinical gene therapy translatability
19. Pharmacokinetics of multiple doses of co‐crystal of tramadol–celecoxib: findings from a four‐way randomized open‐label phase I clinical trial
20. Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ1 Receptor Antagonist Clinical Candidate for the Treatment of Pain
21. Integrative Technologies for Neuropeptide Characterization
22. Opportunities in CNS Drug Discovery and Development
23. Interleukin-1α (IL-1α), IL-1β, IL-1 receptor type I, IL-1 receptor antagonist, and TGF-β1 mRNAs in pediatric astrocytomas, ependymomas, and primitive neuroectodermal tumors
24. Regulation of brain interleukin-1β (IL-1β) system mRNAs in response to pathophysiological concentrations of IL-1β in the cerebrospinal fluid
25. Neural Representation of Sweet Taste in the Cortex of the Monkey
26. High-Throughput siRNA-Based Functional Target Validation
27. Biomarker discovery and validation: technologies and integrative approaches
28. Virus-Based Expression Systems Facilitate Rapid Target In Vivo Functionality Validation and High-Throughput Screening
29. Regional Cytokine, Cytokine Receptor and Neuropeptide mRNA Changes Associated with Behavioral and Neuroanatomical Abnormalities in Persistent, Noninflammatory Virus Infection of Neonatal Rats
30. Co-crystal of tramadol–celecoxib in patients with moderate to severe acute post-surgical oral pain: a dose-finding, randomised, double-blind, placebo- and active-controlled, multicentre, phase II trial
31. A New Pharmacophore Model for the Design of Sigma-1 Ligands Validated on a Large Experimental Dataset
32. Differential Solution Behavior of the New API–API Co-Crystal of Tramadol–Celecoxib (CTC) versus Its Constituents and Their Combination
33. Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic
34. Commentary on the "Co-Crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-Surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre Phase II Trial". Implications for Cardiovascular Safety
35. Cytokines and Ingestive Behavior: Methods and Overview
36. Contributors to Volume 17
37. Cytokine-Induced Anorexia: Behavioral, Cellular, and Molecular Mechanismsa
38. Discovery of EST73502, a Dual μ‑Opioid Receptor Agonist and σ1 Receptor Antagonist Clinical Candidate for the Treatment of Pain.
39. Central nervous system mechanisms contributing to the cachexia–anorexia syndrome
40. Brain mechanisms in cytokine-induced anorexia
41. Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ1Receptor Antagonist Clinical Candidate for the Treatment of Pain
42. Somatomedins (Insulin-Like Growth Factors) and the Nervous System
43. Co-crystal of Tramadol Hydrochloride–Celecoxib (ctc): A Novel API–API Co-crystal for the Treatment of Pain
44. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
45. Acute and Chronic Disease: Neurological Manifestations
46. Considerations for Target Validation and Industrial Approaches
47. Integrated expressional analysis: Application to the drug discovery process
48. Diarylacetylene piperidinyl amides as novel anxiolytics
49. Emerging paradigms in applied bioinformatics
50. Integrative Technologies for Neuropeptide Characterization.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.